EU IVDR – Clinical Evidence and Performance Evaluation

by Andrea Colombo,
MD Compliance Expert – PQE Group

The issues exposed in this article will be discussed in
“In Vitro Diagnostic Medical Device Regulation 746/2017: what to know to be ready” free Webinar by PQE
, on July 8th @11:30 a.m. CET – Register now to secure your presence.

The new Regulation 2017/746 for In Vitro Diagnostic medical devices was published in May 2017 with a 5 years transitional period and application date from May 26th 2022: among the key changes introduced by the regulation, the new requirements for Clinical Evidence are some of those of greatest importance (ref. CHAPTER VI).

Clinical evidence is required as a combination of sufficient amount and quality of clinical data and performance evaluation results pertaining a given device to allow a qualified assessment of whether the device achieves the intended clinical benefit and safety, when used as intended by the manufacturer.

For this purpose, performance evaluation has been now re-defined as a continuous process for collection of clinical evidence to demonstrate the scientific validity, analytical performance and clinical performance of that device for its intended purpose throughout the whole life-cycle.

Performance evaluation plan to be on a continuous basis

Manufacturers shall establish and update a performance evaluation plan specifying the characteristics and the performance of the device and the process and criteria applied to
generate the necessary clinical evidence. The performance evaluation report shall be part of the technical documentation and will be also a key part of the initial submissions to the Notified Body.

The document is intended to provide confirmation of conformity with relevant General Safety and Performance Requirements for the following:

  1. Normal conditions of the intended use of the device
  2. Evaluation of the interference(s) and cross-reaction(s)
  3. Acceptability of the benefit-risk ratio

This living process shall be conducted on continuous basis and shall be kept updated through the implementation of the post market surveillance (PMS) and the post market performance follow up (PMPF).

References for knowledge

Main reference guidance documents that provides information on the definitions and expectations of content for clinical evidence and which may be used as reference material are:

  • GHTF/SG5/N6:2012 – Clinical Evidence for IVD medical devices – Key Definitions and Concepts
  • GHTF/SG5/N7:2012 – Clinical Evidence for IVD medical devices – Scientific Validity Determination
    and Performance Evaluation
  • GHTF/SG5/N8:2012 – Clinical Evidence for IVD Medical Devices – Clinical Performance Studies for
    In Vitro Diagnostic Medical Devices

GHTF = Global harmonization Task Force; now re-convened as the International Medical Devices
Regulators Forum (IMDRF).
For IMDRF guidance documents for clinical evaluation see:
http://www.imdrf.org/documents/doc-ghtf-sg5.asp

Reference standard defining good study practice for the planning, design, conduct, recording and reporting of clinical performance studies carried out to assess the clinical performance and safety of in vitro diagnostic (IVD) medical devices for regulatory purposes is:

  • ISO 20916:2019 In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects — Good study practice

Want to know more?

Learn everything you need to know about IVDR 2017/746 regulation:

Join our Live Webinar on july 8th for interactive in-depth analysis & considerations, and claim your FREE ebook, available for all attendees!

 

PQE Group is always ready to support your business achieving and maintaining compliance for your IVD medical devices. visit our Compliance services page to know more about, or contact us and our team will be glad to discuss the best solutions for your business.

Related Articles